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Juvenile bullous pemphigoid (BP) manifests clinically 
as blisters arising over an erythematous or urticarial 
base before the age of 18 years. Its diagnosis is based on 
similar criteria as in adult patients (1, 2). Some authors 
distinguish early childhood BP (3) from BP in adoles-
cence, which is rarer (4). In recent years, the incidence 
of BP has increased in Finland (5), but the incidence of 
juvenile BP is unknown. To our knowledge, we report 
here the 3 first Nordic cases of juvenile BP. The main 
characteristics of the cases are summarized in Table SI1.
CASE REPORTS
Case 1. A 13-year-old Finnish girl with a history of atopia de-
veloped pruritic erythematous papules on the extremities. After 
1 month, tense and flaccid blisters developed on her palms and 
soles (Fig. 1A, B). Direct immunofluorescence (DIF), circulating 
serum BP180 antibodies and elevated eosinophilia supported 
the diagnosis of BP. The blisters resolved after initiation of oral 
prednisolone (OP) of 60 mg/day (1 mg/kg/day). Adverse effects 
prompted tapering of systemic corticosteroids and discontinuation 
3 months later. During tapering of prednisolone, oral methotrexate 
was initiated, at 15 mg/week, and showed a good response within 
3 months. Six months after initiation of methotrexate BP180 anti-
bodies were undetectable. One year after onset of BP the patient 
was still in remission and methotrexate could be discontinued.
Case 2. A 3-year-old boy with a history of iritis and juvenile poly-
arthritis and treatment with methotrexate, 5 mg/week, and inflixi-
mab, 100 mg every 8 weeks, presented with a sudden generalized 
eruption of erythematous maculo-papules on the face, limbs and 
trunk. Pruritic and tense over 1-cm sized blisters were formed on 
the limbs and soles (Fig. 1C, D). There was minor involvement 
of the oral mucosa. The patient had no fever or elevation of in-
fection markers. Biopsy, DIF and circulating BP180 antibodies 
confirmed BP. OP was initiated at a dose of 30 mg (1.9 mg/kg/
day) with methotrexate 10 mg/week, with a good response. OP 
was discontinued after 2.5 years of treatment. Corticodependence 
was observed when decreasing by between 5 and 10 mg/day with 3 
relapses of BP. An exacerbation of polyarthritis further prolonged 
the long-term tapering of the drug. Dapsone 25 mg/day for 2 
months was ineffective. Intravenous immunoglobulins (IVIg), 
15 g every 2 weeks, induced remission, but was not sufficient to 
prevent new eruptions when methotrexate was paused and the dose 
of prednisolone further tapered, thus indicating the need for very 
slow corticosteroid tapering. One year and 4 months from starting 
IVIg, time intervals between the infusions were slowly increased 
from 2 to 16 weeks. Infliximab was paused when IVIg treatment 
was initiated, but reintroduced 3 years from onset of BP symptoms, 
and did not trigger a flare of BP. Six years after the diagnosis, 
BP180 antibody levels remain slightly elevated (13 U/ml), while 
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Fig. 1. Clinical photographs of patients with juvenile bullous pemphigoid (BP). (A, B) Case 1: Pruritic papular lesions on the extremities were 
followed by formation of serous and haemorrhagic bullae on the soles and medial arches of the feet. (C, D) Case 2: Widespread bullous and crusted 
lesions on erythematous base mainly affecting the skin of the extremities. (E, F) Case 3: Widespread erythematous plaques and annular lesions on the 
face, trunk and limbs alongside vesiculobullous lesions on all 4 extremities.
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the patient was still on methotrexate 10 mg/week, infliximab and 
IVIg. IVIg treatment has, thus far, continued for 6 years.
Case 3. A 3-month-old male infant presented with a sudden erup-
tion of vesiculo-bullous lesions on the hands and soles, followed 
by widespread erythematous and urticarial plaques on the face, 
limbs and trunk. Serous bullae appeared later on the extremities 
mimicking clinically linear IgA disease (Fig 1E, F). The patient 
had received DTaP-IPV-Hib, rotavirus and pneumococcal con-
jugate vaccination 7 days before onset of skin symptoms. DIF 
and circulating BP180 antibodies confirmed BP diagnosis. Oral 
clarithromycin, 15 mg/kg/day, for 3 weeks in combination with 
topical low-potency corticosteroid treatment improved the skin 
symptoms. After 1 month, no new lesions appeared and by 4 
months all lesions and pruritus had resolved. There were no signs 
of BP during the follow-up period of 8 months, by which time 
BP180 antibodies had decreased to 9 U/ml.
DISCUSSION 
With fewer than 100 reported cases in the literature, 
juvenile BP is a rare acquired autoimmune disorder (6). 
The diagnostic features are similar for both paediatric and 
adult patients, and therefore juvenile BP should be seen 
as part of the same disease entity. However, the clinical 
hallmark of juvenile BP is acral distribution of skin le-
sions and frequent mucosal involvement, which are rare 
in adult patients with BP (7). Females are more frequently 
represented than males in the literature (62% vs. 38%) 
(3). Since BP and epidermolysis bullosa acquisita (EBA) 
display similar findings on DIF, Welfringer-Morin et al. 
(8) suggested using BP180, BP230, and anticollagen 
VII antibodies to differentiate both conditions. All of 
our cases presented high levels of circulating BP180 
antibodies, which favoured pemphigoid rather than EBA.
There have been some reported cases of infliximab-
induced BP (9). In case 2, the onset of BP was considered 
unrelated to infliximab. However, a similar cytokine 
profile of BP and juvenile arthritis might have been a 
predisposing factor for BP. In case 3, BP occurred one 
week after vaccination. In infantile BP onset of skin 
symptoms have been reported to occur within 2 weeks 
from vaccinations (10). Only larger studies could confirm 
whether the association is fortuitous. However, BP is not 
a contraindication to continue immunization.
Juvenile BP often runs a self-limiting course, with 
frequent spontaneous remission. Remission is reached 
within 1 year from disease onset and relapses are rare 
(11). Case 3 illustrates this typical course with a drama-
tic disease onset and rapid resolution of lesions with no 
following relapse. On the other hand, case 2 was chal-
lenging with a long duration of symptoms after diagnosis 
and still slightly elevated levels of BP180 antibodies 
several years later.
In adolescence, BP requires less hospitalization than 
other autoimmune bullous disorders (12). The rapid onset 
of widespread lesions and demanding topical treatment 
led to hospitalization in all 3 cases. Most commonly used 
treatments are oral corticosteroids and dapsone. Other 
successful treatment regimens include among others er-
ythromycin, azathioprine, mycophenolate mofetil, IVIg 
and rituximab (13). Methotrexate has also showed good 
responses in some cases of juvenile BP (14). Two of our 
patients received methotrexate, case 1 as second-line 
treatment for BP and case 2 for polyarthritis prior to BP 
onset. In case 1 the response to methotrexate was rapid. 
It is likely that, in case 2, the onset of BP symptoms were 
somewhat postponed by methotrexate and triggered when 
the medication was paused. Based on these favourable 
experiences, methotrexate could be regarded as a possible 
treatment option in juvenile BP. After initial disease con-
trol the treatment should be based on the least aggressive 
therapy and lowest possible doses that prevent relapses. 
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